PROMOMED expands the geography of its presence: The company has opened an international division in China

Opening of the international division of Promomed Peking Pharmaceutical Co., Ltd. It reflects the focus on innovative technologies and the growing demand for the Group's existing drug solutions in the Asia-Pacific region. The event took place on the territory of the Trade Representative Office of the Russian Federation in the People's Republic of China.

The priority of Promomed Peking Pharmaceutical Co., Ltd. will be to conduct international clinical trials and go through the registration procedure for the Group's original drugs, ensuring the availability of drugs for the treatment of socially significant diseases both in Russia and abroad. The company plans to develop partnerships with leading players in the pharmaceutical and scientific sectors of the People's Republic of China. The work will focus on several strategic areas, from forming stable relationships with commercial organizations, manufacturers of high—tech equipment and specialized development companies to joint projects with scientific institutes. The cooperation will focus on expanding the evidence base of our own portfolio of drugs, obtaining new biologically active molecules, conducting large-scale clinical trials and introducing drugs into the healthcare system in different countries of the world.

"The opening of the PROMOMED Group representative office in Beijing is an important milestone in the organization of a systemic technological partnership between Russia and China in the field of pharmaceuticals. This event is of particular importance for Mordovia, where the Biochemist plant, the key scientific and production base of the Company, is located. We are ready to create favorable conditions for the development of the domestic pharmaceutical industry. Turning the interstate dialogue into concrete joint developments and the latest molecules put into practice is to strengthen the export opportunities of the whole country and the health of millions of people," said Artem Zdunov, Head of the Republic of Mordovia.

As a result of discussions with representatives of the Chinese scientific and medical community, a unique neuroprotector of the Group, Brainmax®, was selected as the first priority project for international cooperation.[1]

"The issues of cognitive longevity, preventing severe consequences of stroke, and maintaining high brain performance under stress and stress are attracting the attention of scientists around the world. New original neuroprotectors are needed to solve them. We have carefully studied a wide range of publications on the unique mechanism of action of the Russian drug Brainmax®. We are pleased to continue its research in China and see great potential for including the drug in national clinical guidelines," Yu noted. Jian, Professor, Military doctor, CEO of Chongqing Ryan Pharmaceutical., Ltd.

An important element of the work will be interaction with representatives of Chinese government authorities within the framework of existing regulatory procedures and practices.

During the meeting with representatives of PROMMED, the leadership of Beijing's Wangfujing district noted the importance for the development of bilateral relations. According to representatives of the administration, the development of bilateral ties serves the interests of society and contributes to the preservation of human health and prosperity.

"We see great potential in combining our research and industrial capacities with Chinese developers and look forward to the massive introduction of joint innovations in key areas, including the development of multi-targeted biotechnological drugs and personalized therapeutics. Cooperation opens up wide opportunities for joint international research, which will serve as the basis for the formation of a reliable evidence base for our solutions. Ahead of us lies the development of more complex technologies and the scaling of high—precision developments for the benefit of the health of millions of people," said Peter Bely, Chairman of the Board of Directors of PROMOMED.

Representatives of the authorities from China and Russia, as well as key partners from China, took part in the solemn event dedicated to the opening of the Company. During the business program, the parties discussed and fixed the priority areas of cooperation.

________________________

[1] This drug is a prescription drug and should only be purchased as prescribed by a doctor. The drug has contraindications. Please read the instructions for use. Do not use the drug unless it has been prescribed to you by your doctor. When using the drug, always follow the instructions for use and the recommendations of your doctor.